Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2025,
Relief Therapeutics Holding receivedCHF0.19 Mil more from issuing new shares than it paid to buy back shares.
It spentCHF0.24 Mil paying down its debt.
It paidCHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedCHF0.00 Mil from paying cash dividends to shareholders.
It spentCHF0.00 Mil on other financial activities.
In all, Relief Therapeutics HoldingspentCHF0.06 Mil on financial activities for the
six
months ended in Jun. 2025.
Relief Therapeutics Holding (XSWX:RLF) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Relief Therapeutics Holding's issuance of stock for the
six
months ended in Jun. 2025 was CHF0.19 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Relief Therapeutics Holding's repurchase of stock for the
six
months ended in Jun. 2025 was CHF0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Relief Therapeutics Holding's net issuance of debt for the
six
months ended in Jun. 2025 was CHF-0.24 Mil.
Relief Therapeutics Holding spentCHF0.24 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Relief Therapeutics Holding's net issuance of preferred for the
six
months ended in Jun. 2025 was CHF0.00 Mil.
Relief Therapeutics Holding paidCHF0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Relief Therapeutics Holding's cash flow for dividends for the
six
months ended in Jun. 2025 was CHF0.00 Mil.
Relief Therapeutics Holding receivedCHF0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Relief Therapeutics Holding's other financing for the
six
months ended in Jun. 2025 was CHF-0.00 Mil.
Relief Therapeutics Holding spentCHF0.00 Mil on other financial activities.
Relief Therapeutics Holding Cash Flow from Financing Related Terms
Relief Therapeutics Holding Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding Cash Flow from Financing Chart
Relief Therapeutics Holding Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Relief Therapeutics Holding's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF-0.30 Mil mean?
Relief Therapeutics Holding (XSWX:RLF) has a Cash Flow from Financing of CHF-0.30 Mil as of Jun. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Cash Flow from Financing too high?
Relief Therapeutics Holding's current Cash Flow from Financing is CHF-0.30 Mil. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Cash Flow from Financing compare to KTTA and OSRH?
Relief Therapeutics Holding's Cash Flow from Financing of CHF-0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Cash Flow from Financing is CHF-0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Cash Flow from Financing of CHF-0.30 Mil. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Cash Flow from Financing is CHF-0.30 Mil. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Cash Flow from Financing is CHF-0.30 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Cash Flow from Financing: CHF-0.30 Mil
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
